SRZN — Surrozen, Inc.

Surrozen (SRZN) Q4 2022 Earnings Call Summary

1. Key Financial Results and Metrics

• Cash, cash equivalents, and marketable securities stood at approximately $76 million at the end of 2022.
• The company anticipates a cash runway extending into the second half of 2024.
• A restructuring plan was implemented, aiming for a 15% reduction in operating expenses (excluding noncash and nonrecurring charges) in 2023 compared to 2022.

2. Strategic Updates and Business Highlights

• Surrozen is focused on leveraging its proprietary Wnt pathway technology to develop tissue-selective antibodies for a range of diseases, particularly in liver and inflammatory bowel disease (IBD).
• The company has two lead clinical programs:
  • SZN-043 for severe alcoholic hepatitis, which has enrolled its first patient in a Phase I trial.
  • SZN-1326 for inflammatory bowel disease, which is also in a Phase I trial but has faced temporary pauses due to safety concerns.
• Surrozen entered a partnership with Boehringer Ingelheim for the development of SZN-413, a Wnt agonist for retinal diseases, with a potential milestone payment of $10 million expected by year-end 2023.

3. Forward Guidance and Outlook

• Data from the Phase I trial for SZN-043 in chronic liver disease patients is expected by the end of 2023, with plans to initiate a Phase Ib trial in severe alcoholic hepatitis in 2024.
• For SZN-1326, the company plans to resume dosing in healthy volunteers soon, with proof-of-concept data anticipated in the second half of 2024.
• The company is also looking to advance additional research programs in ophthalmology and corneal diseases.

4. Bad News, Challenges, or Points of Concern

• The company reported adverse events related to liver enzyme elevations (transaminase) in both SZN-043 and SZN-1326 trials, leading to a voluntary pause in the SZN-1326 study for further evaluation.
• There is uncertainty regarding the safety of SZN-1326 in hepatically impaired patients, and the company has not identified a specific mitigation strategy for these adverse events.
• The potential for liver-related adverse effects raises concerns about the therapeutic index and the translatability of animal model data to human subjects.

5. Notable Q&A Insights

• Management clarified that the Phase I study for SZN-043 is targeting chronic liver disease patients, which may include those with fibrosis but not necessarily cirrhosis.
• The dosing strategy for SZN-1326 will follow a minimal anticipated biological effect level (MABEL) approach, with further cohorts planned to explore safety and efficacy.
• Questions from analysts highlighted concerns about the observed adverse events and the potential implications for future dosing regimens and patient safety, particularly in the context of liver health.

Overall, while Surrozen is advancing its clinical programs and has a solid financial position, it faces significant challenges related to safety concerns that could impact the trajectory of its lead candidates.